Suraksha Diagnostic Ltd

Suraksha Diagnostic Ltd

₹ 324 0.51%
04 Jul - close price
About

Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution.[1]

Key Points

Business Model[1][2]
a) Integrated Services: Offers a one-stop solution for pathology, radiology, and medical consultancy services.
b) Comprehensive Testing: Provides 2,300+ diagnostic tests, ranging from routine pathology to advanced radiology.
c) Hub and Spoke Model: Operates through a central reference lab, 8 satellite labs, and a network of diagnostic and collection centers for efficient sample processing and service delivery.
d) Omni-channel Consultation: Combines online and offline medical consultation services, leveraging its polyclinics with 750+ doctors.
e) B2C-Focused Revenue Model: Primarily serves individual patients, with some revenue from B2B contracts.

Diagnostic Test Data[1][3]
a) Pathology Tests:
788 Routine Tests: Basic biochemistry, hematology.
664 Specialized Tests: Advanced biochemistry, histopathology, molecular pathology.

b) Radiology Tests:
766 Basic/Intermediate Tests: X-rays, USG, CT scans.
119 Advanced Tests: MRI scans, specialized CT scans.
Equipment: 24 CT and 13 MRI machines.

c) Testing Volume:
Q1 FY25: 1.58 million tests (0.28 million patients).
FY24: 5.98 million tests (1.14 million patients).

Geographical Presence [4]
West Bengal is their core market accounting for 95.34% of Q1 FY25 revenue. It also has a presence across Bihar, Assam, and Meghalaya. As of FY24, the company has a 1.15-1.3% market share in eastern India.

  • Market Cap 1,686 Cr.
  • Current Price 324
  • High / Low 449 / 231
  • Stock P/E 50.4
  • Book Value 41.2
  • Dividend Yield 0.00 %
  • ROCE 18.2 %
  • ROE 17.0 %
  • Face Value 2.00

Pros

Cons

  • Stock is trading at 7.87 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 9.60% over past five years.
  • Company has a low return on equity of 13.3% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
60.05 51.45 55.37 60.43 65.95 58.57 64.15
39.00 35.87 35.44 39.32 42.39 40.48 44.33
Operating Profit 21.05 15.58 19.93 21.11 23.56 18.09 19.82
OPM % 35.05% 30.28% 35.99% 34.93% 35.72% 30.89% 30.90%
0.72 0.83 0.27 1.21 1.26 0.97 0.94
Interest 2.43 1.98 2.12 2.22 2.07 2.03 2.06
Depreciation 7.95 7.92 8.33 8.88 8.58 8.62 8.66
Profit before tax 11.39 6.51 9.75 11.22 14.17 8.41 10.04
Tax % 24.06% 24.27% 29.85% 25.76% 24.21% 24.49% 20.22%
8.65 4.93 6.84 8.33 10.75 6.36 8.01
EPS in Rs 125.36 71.45 99.13 1.93 2.49 1.22 1.54
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
151 158 140 223 190 219 249
115 123 115 175 142 144 166
Operating Profit 36 34 25 48 48 74 83
OPM % 24% 22% 18% 22% 25% 34% 33%
1 2 -1 2 1 1 4
Interest 2 2 2 2 10 10 8
Depreciation 12 13 16 15 32 33 35
Profit before tax 23 21 6 33 8 33 44
Tax % 17% 28% -1% 28% 9% 25% 24%
19 15 6 24 7 24 33
EPS in Rs 276.09 220.43 93.77 344.20 104.20 353.33 6.42
Dividend Payout % 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 10%
3 Years: 4%
TTM: 14%
Compounded Profit Growth
10 Years: %
5 Years: 17%
3 Years: 12%
TTM: 26%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 13%
3 Years: 13%
Last Year: 17%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 7 7 7 7 7 7 10
Reserves 96 111 118 141 148 172 204
22 13 18 21 99 92 89
43 42 28 32 29 30 30
Total Liabilities 168 173 171 201 282 302 333
127 128 119 119 195 211 216
CWIP 0 0 0 1 2 1 5
Investments 2 5 6 0 0 1 3
38 39 46 80 84 88 109
Total Assets 168 173 171 201 282 302 333

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
31 24 42 45 61 63
-20 -28 -44 -22 -35 -39
-10 3 1 -24 -26 -24
Net Cash Flow 1 -1 -0 -1 0 -1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 16 14 16 12 9 15 22
Inventory Days 107 93 62 38 81 89 101
Days Payable 176 227 177 84 184 192 176
Cash Conversion Cycle -54 -120 -99 -34 -95 -88 -53
Working Capital Days 6 -35 -2 -4 -16 -11 8
ROCE % 18% 8% 23% 9% 17% 18%

Shareholding Pattern

Numbers in percentages

9 Recently
Dec 2024Mar 2025
48.78% 48.78%
15.39% 14.46%
20.43% 22.05%
15.39% 14.71%
No. of Shareholders 98,66287,275

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents